Literature DB >> 16101191

Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma.

Jorge Ortiz-González1, Nora Patricia Alvarez-Aguila, Juan Manuel Medina-Castro.   

Abstract

BACKGROUND: The serum level of carbohydrate antigen 19-9 (CA 19-9) depends on the tumor size and differentiation grade. Jaundice can cause an elevation of serum CA 19-9, although the nature of this interaction is not fully understood. PATIENTS AND METHODS: This was a retrospective study of 26 patients with potentially resectable pancreatic adenocarcinoma. Serum CA 19-9 was correlated with the histological differentiation. CA 19-9 adjusted for serum bilirubin was determined and analyzed.
RESULTS: No correlation between CA 19-9 and histological differentiation was determined (p>0.05). The median adjusted CA 19-9 level was significantly lower (p=0.01) in patients with normal biliary excretion than those with bilirubin levels >2 mg/dL.
CONCLUSION: These data are consonant with the theory of a dual contribution to the serum CA 19-9 level from biliary obstruction and tumor cell synthesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101191

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

2.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  Indian J Surg Oncol       Date:  2011-02-17

3.  Preoperative Alkaline Phosphatase-adjusted CA19-9 as a Superior Prognosticator for Extrahepatic Biliary Tract Cancer With Jaundice.

Authors:  Shinichi Ikuta; Tsukasa Aihara; Takayoshi Nakajima; Meidai Kasai; Naoki Yamanaka
Journal:  Cancer Diagn Progn       Date:  2022-09-03

4.  Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.

Authors:  Sinziana Dumitra; Mohammad H Jamal; Jad Aboukhalil; Suhail A Doi; Prosanto Chaudhury; Mazen Hassanain; Peter P Metrakos; Jeffrey S Barkun
Journal:  HPB (Oxford)       Date:  2013-03-22       Impact factor: 3.647

5.  Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.

Authors:  Gaetano La Greca; Maria Sofia; Rosario Lombardo; Saverio Latteri; Agostino Ricotta; Stefano Puleo; Domenico Russello
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

6.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375

7.  Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.

Authors:  Jeannine Bachmann; Knut Ketterer; Christiane Marsch; Kerstin Fechtner; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  BMC Cancer       Date:  2009-07-28       Impact factor: 4.430

8.  Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria.

Authors:  Casper van Eijck; Stefan Löb; Friedrich Anger; Anna Döring; Jacob van Dam; Johan Friso Lock; Ingo Klein; Max Bittrich; Christoph-Thomas Germer; Armin Wiegering; Volker Kunzmann
Journal:  Ann Surg Oncol       Date:  2020-09-12       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.